ALIGNMENT HEALTHCARE INC
ALHCNASDAQTrading Snapshot
- Day Range
- $13.40 – $13.79
- 52-Week Range
- $13.05 – $25.12
- Volume
- $3.97B
- Avg Volume
- $5.12B
- Shares Outstanding
- 206.7M
- Next Earnings
- Sep 23, 2026
Fundamentals Snapshot
- Annual Revenue
- $3.95B
- Last Q Revenue
- $1.34B
- P/E Ratio
- 70.2
- P/S Ratio
- 0.6x
- EPS (TTM)
- $0.19
- Dividend Yield
- —
Why Investors Own ALHC
- ✓High-growth profile — revenue up +40.8% YoY with expanding US Equity exposure.
- ✓Healthy economics — 54% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About ALIGNMENT HEALTHCARE INC
Alignment Healthcare, Inc. is a technology-driven Medicare Advantage provider operating a healthcare platform focused squarely on the consumer. This organization delivers personalized medical services across the United States, primarily for elderly individuals and others requiring specific support, leveraging its suite of Medicare Advantage plans. The company directly owns and operates Medicare Advantage programs in California, North Carolina, and Nevada. Beyond its proprietary offerings, it also orchestrates and furnishes essential healthcare services—including professional, institutional, and supplementary care—for beneficiaries of select plans from unrelated Medicare Advantage Health Maintenance Organizations. Established in 2013, Alignment Healthcare maintains its corporate base in Orange, California.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
Alignment Healthcare: The Drawdown I Told You To Wait For Has Arrived (Rating Upgrade)
Alignment Healthcare (ALHC) upgraded to Buy after a 38% drawdown; Q2 beat, guidance raised and 40%+ upside.
JP Morgan Maintains Overweight on Alignment Healthcare, Lowers Price Target to $22
JP Morgan analyst John Stansel maintains Alignment Healthcare (NASDAQ:ALHC) with a Overweight and lowers the price target from $26 to $22.
Raymond James Downgrades Alignment Healthcare to Outperform, Lowers Price Target to $19
Raymond James analyst John Ransom downgrades Alignment Healthcare (NASDAQ:ALHC) from Strong Buy to Outperform and lowers the price target from $22 to $19.
Alignment Healthcare, Inc. (ALHC) Q2 2026 Earnings Call Transcript
Alignment Healthcare, Inc. (ALHC) Q2 2026 Earnings Call July 30, 2026 5:00 PM EDTCompany ParticipantsJohn Kao - Founder, Chairman & CEOJames Head -...
Thursday's after hours session: top gainers and losers
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Alignment Healthcare (NASDAQ:ALHC) Beats Q2 Earnings but Guidance Miss Sends Shares Tumbling
Alignment Healthcare beat Q2 earnings but stock fell 14% after hours as full-year revenue guidance missed estimates, overshadowing strong membership growth.